Skip to main content
. 2023 Jul 13;14:1150667. doi: 10.3389/fimmu.2023.1150667

Table 1.

Overview of study cohort. Data indicate median (interquartile range) or absolute numbers (percentage).

Characteristics Patients with Delta breakthrough infection (N=25) Patients with Omicron-BA.1 breakthrough infection (N=15) Patients with Omicron-BA.5 breakthrough infection (N=12) Uninfected controls (N=28) p
Sex:
Men (%) 17 (68) 10 (66.7) 4 (33.3) 14 (50) n.s.
Women (%) 8 (32) 5 (33.3) 8 (66.7) 14 (50)
Age:
Total 73 (51-82) 60 (55-77) 69 (62-79) 53 (49-63) C-BA.5 and C-D: p<0.01
2 doses of vaccine 71 (49-83) 58 (44-63) N/A 52 (48-64) C-D: p=0.0457
Booster vaccination 71 (60-81) 74 (55-82) 69 (62-79) 54 (50-61) C-BA.1 and C-BA.5: p<0.01
Vaccine:
Comirnaty® (BioNTech/Pfizer) (%) 23 (92) 8 (53.3) 6 (50) 15 (53.6) D-BA.1, D-BA.5 and C-D: p<0.01
Spikevax® (Moderna) (%) 1 (4) 2 (13.3) 0 12 (42.9) C-BA.5 and C-D: p<0.01
Janssen® (Johnson & Johnson) (%) 1 (4) 0 0 0 n.s.
Combination (%) 0 5 (33.3) 5 (41.7) 1 (3.6) D-BA-1, D-BA-5 and C-BA.5: p<0.01; C-BA.1: p<0.05
Unknown (%) 0 0 1 (8.3) 0 n.s.
Vaccine doses:
1 (%) 1 (4) 1 (6.7) 0 0 n.s.
2 (%) 22 (88) 8 (53.3) 0 16 (57.1) D-BA.1 and C-D: p<0.05; D-BA.5: p<0.0001; BA.1-BA.5: 0.01; C-BA.5: p<0.001
3 (%) 2 (8) 6 (40) 10 (83.3) 10 (35.7) D-BA.1, BA.1-BA.5, C-D and C-BA.5: p<0.05; D-BA.5: p<0.0001
4 (%) 0 0 2 (16.7) 2 (7.1) n.s.
Days since vaccination:
Total 149.5 (97-184.3) 134.5 (66.25-192.5) 184.5 (133-222.5) 186 (45.75-199.5) n.s.
Since 2nd vaccination 160 (113-188) 176 (90.5-229.3) N/A 54 (29-186) D-C: p=0.0414
Since booster 96.5 (91-102) 69 (46-140) 184.5 (133-222.5) 199 (192.3-208) D-BA.5, BA.1-BA.5 and D-C: p<0.05; C-BA.1: p<0.01
Unknown 7 1 4 0

Data indicate median (interquartile range) or absolute numbers (percentage).

Differences between groups for the categorical variables were analyzed by Fisher’s exact test and for the continuous variables by two-tailed Mann-Whitney U test. N/A, not applicable; D, Delta; C, uninfected control; n.s., not significant.